使用新型盒式系统对莫西沙星治疗结核分枝杆菌感染的体内药代动力学和药效学进行建模。
Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
作者信息
Ginsburg Amy Sarah, Lee Jin, Woolwine Samuel C, Grosset Jacques H, Hamzeh Fayez M, Bishai William R
机构信息
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
出版信息
Antimicrob Agents Chemother. 2005 Feb;49(2):853-6. doi: 10.1128/AAC.49.2.853-856.2005.
Abstract
To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.
摘要
为研究莫西沙星治疗结核病的疗效，我们采用了一种新型药筒系统来模拟体内药代动力学。我们发现该系统是一种用于模拟体内药代动力学的可靠方法，并提供了支持间歇性莫西沙星治疗作为抗结核化疗组成部分的效用的数据。
相似文献
1
Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
Antimicrob Agents Chemother. 2005 Feb;49(2):853-6. doi: 10.1128/AAC.49.2.853-856.2005.
2
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
J Infect Dis. 2004 Nov 1;190(9):1642-51. doi: 10.1086/424849. Epub 2004 Sep 24.
3
Moxifloxacin treatment of tuberculosis.
Antimicrob Agents Chemother. 2004 Sep;48(9):3642; author reply 3642-3. doi: 10.1128/AAC.48.9.3642-3643.2004.
4
Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
Antimicrob Agents Chemother. 2010 Jun;54(6):2534-9. doi: 10.1128/AAC.01761-09. Epub 2010 Apr 12.
5
Pharmacokinetics of subconjunctival injection of moxifloxacin in humans.
Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):1019-20. doi: 10.1007/s00417-012-2036-2. Epub 2012 May 3.
6
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2005 Feb;49(2):685-9. doi: 10.1128/AAC.49.2.685-689.2005.
7
In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
Antimicrob Agents Chemother. 2007 Sep;51(9):3401-3. doi: 10.1128/AAC.01520-06. Epub 2007 Jun 18.
8
[The role of moxifloxacin in the prophylaxis of post-surgical endophthalmitis].
Arch Soc Esp Oftalmol. 2010 Oct;85(10):323-4. doi: 10.1016/j.oftal.2010.11.005.
9
Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.
Neurocrit Care. 2005;2(3):325-9. doi: 10.1385/NCC:2:3:325.
10
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. doi: 10.1128/AAC.00414-06. Epub 2006 Dec 4.
引用本文的文献
1
Preclinical Efficacy Testing of New Drug Candidates.
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
2
Assessment of the Efficacy of New Anti-Tuberculosis Drugs.
Open Infect Dis J. 2008 Dec;2:59-76. doi: 10.2174/1874279300802010059.
3
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
Future Med Chem. 2010 Aug;2(8):1355-69. doi: 10.4155/fmc.10.224.
4
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
Antimicrob Agents Chemother. 2011 Jan;55(1):24-34. doi: 10.1128/AAC.00749-10. Epub 2010 Oct 11.
本文引用的文献
1
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
2
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6. doi: 10.1164/rccm.200310-1380OC. Epub 2003 Oct 24.
3
Fluoroquinolones, tuberculosis, and resistance.
Lancet Infect Dis. 2003 Jul;3(7):432-42. doi: 10.1016/s1473-3099(03)00671-6.
4
Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2003 Feb;47(2):653-7. doi: 10.1128/AAC.47.2.653-657.2003.
5
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Antimicrob Agents Chemother. 2002 Jun;46(6):1875-9. doi: 10.1128/AAC.46.6.1875-1879.2002.
6
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Antimicrob Agents Chemother. 2001 Mar;45(3):673-8. doi: 10.1128/AAC.45.3.673-678.2001.
7
Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.
Antimicrob Agents Chemother. 1999 Jul;43(7):1560-4. doi: 10.1128/AAC.43.7.1560.
8
Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Antimicrob Agents Chemother. 1999 May;43(5):1118-23. doi: 10.1128/AAC.43.5.1118.
9
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Antimicrob Agents Chemother. 1999 Mar;43(3):672-7. doi: 10.1128/AAC.43.3.672.
10
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 1999 Jan;43(1):85-9. doi: 10.1128/AAC.43.1.85.
Zotero 插件